Clinical Trial Update: Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer [Phase 2]

View source ↗

Summary

Disitamab Vedotin is being studied in combination with Bacillus Calmette-Guérin (BCG) therapy for HER2-expressing high-risk non-muscle invasive bladder cancer i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Bacillus Calmette-Guérin (BCG) (Bacillus Calmette-Guérin)
• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: Fudan University | Conditions: Non-muscle Invasive Bladder Cancer, HER-2 Protein Overexpression | Phase 2 | Status: RECRUITING